Compare Stocks: SPRB, PRME, CBIO, and EPRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CBIO Crescent Biopharma	$14.76 +1.6%	$17.04	$8.72 ▼ $27.41	$539.70M	1.24	541,893 shs	684,623 shs
EPRX Eupraxia Pharmaceuticals	$8.31 +1.2%	$7.26	$5.25 ▼ $9.32	$533.81M	1.07	583,716 shs	645,104 shs
PRME Prime Medicine	$3.09 +7.3%	$3.24	$2.67 ▼ $6.94	$521.46M	2.34	3.09 million shs	3.59 million shs
SPRB Spruce Biosciences	$47.27 -0.5%	$51.49	$7.88 ▼ $240.00	$136.54M	3.31	108,531 shs	84,184 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CBIO Crescent Biopharma	+3.86%	-10.58%	-18.14%	-19.28%	+16.89%
EPRX Eupraxia Pharmaceuticals	+2.50%	-4.98%	+22.90%	+24.21%	+43.03%
PRME Prime Medicine	-0.69%	-9.72%	-20.22%	-21.95%	-43.75%
SPRB Spruce Biosciences	-2.48%	-11.53%	-21.83%	-12.02%	+508.32%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CBIO Crescent Biopharma	$14.76 +1.6%	$17.04	$8.72 ▼ $27.41	$539.70M	1.24	541,893 shs	684,623 shs
EPRX Eupraxia Pharmaceuticals	$8.31 +1.2%	$7.26	$5.25 ▼ $9.32	$533.81M	1.07	583,716 shs	645,104 shs
PRME Prime Medicine	$3.09 +7.3%	$3.24	$2.67 ▼ $6.94	$521.46M	2.34	3.09 million shs	3.59 million shs
SPRB Spruce Biosciences	$47.27 -0.5%	$51.49	$7.88 ▼ $240.00	$136.54M	3.31	108,531 shs	84,184 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CBIO Crescent Biopharma	+3.86%	-10.58%	-18.14%	-19.28%	+16.89%
EPRX Eupraxia Pharmaceuticals	+2.50%	-4.98%	+22.90%	+24.21%	+43.03%
PRME Prime Medicine	-0.69%	-9.72%	-20.22%	-21.95%	-43.75%
SPRB Spruce Biosciences	-2.48%	-11.53%	-21.83%	-12.02%	+508.32%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CBIO Crescent Biopharma	2.83	Moderate Buy	$29.60	100.54% Upside
EPRX Eupraxia Pharmaceuticals	2.90	Moderate Buy	$17.80	114.20% Upside
PRME Prime Medicine	2.90	Moderate Buy	$7.47	141.82% Upside
SPRB Spruce Biosciences	2.77	Moderate Buy	$158.33	234.96% Upside

Current Analyst Ratings Breakdown

Latest SPRB, PRME, CBIO, and EPRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/28/2026	PRME Prime Medicine	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/25/2026	PRME Prime Medicine	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/25/2026	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00
9/24/2026	EPRX Eupraxia Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$25.00
9/24/2026	EPRX Eupraxia Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$17.00
9/24/2026	SPRB Spruce Biosciences	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$144.00
9/18/2026	SPRB Spruce Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
9/17/2026	SPRB Spruce Biosciences	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$149.00
9/16/2026	SPRB Spruce Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/14/2026	CBIO Crescent Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$27.00
8/31/2026	PRME Prime Medicine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 9/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CBIO Crescent Biopharma	$10.84M	50.57	N/A	N/A	$14.32 per share	1.03
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	$1.41 per share	N/A
PRME Prime Medicine	$4.63M	121.05	N/A	N/A	$0.67 per share	4.61
SPRB Spruce Biosciences	$4.91M	27.63	N/A	N/A	$39.72 per share	1.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CBIO Crescent Biopharma	-$153.94M	-$6.72	N/A	N/A	N/A	N/A	-101.50%	-86.86%	11/5/2026 (Estimated)
EPRX Eupraxia Pharmaceuticals	-$38.58M	-$1.02	N/A	N/A	N/A	N/A	-63.97%	-43.32%	11/3/2026 (Estimated)
PRME Prime Medicine	-$201.14M	-$1.06	N/A	N/A	N/A	-4,613.11%	-188.27%	-59.11%	N/A
SPRB Spruce Biosciences	-$38.97M	-$39.78	N/A	N/A	N/A	N/A	-123.53%	-90.35%	11/9/2026 (Estimated)

Latest SPRB, PRME, CBIO, and EPRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	SPRB Spruce Biosciences	-$5.79	-$6.68	-$0.89	-$6.68	N/A	N/A
8/11/2026	Q2 2026	EPRX Eupraxia Pharmaceuticals	-$0.25	-$0.23	+$0.02	-$0.23	N/A	N/A
8/6/2026	Q2 2026	PRME Prime Medicine	-$0.24	-$0.24	N/A	-$0.24	$4.40 million	$1.15 million
7/30/2026	Q2 2026	CBIO Crescent Biopharma	-$0.7357	-$0.74	-$0.0043	-$0.74	$0.36 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CBIO Crescent Biopharma	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	N/A	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CBIO Crescent Biopharma	N/A	9.66	9.66
EPRX Eupraxia Pharmaceuticals	0.02	16.00	16.00
PRME Prime Medicine	N/A	3.05	3.05
SPRB Spruce Biosciences	0.05	9.23	9.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CBIO Crescent Biopharma	75.19%
EPRX Eupraxia Pharmaceuticals	N/A
PRME Prime Medicine	70.37%
SPRB Spruce Biosciences	91.71%

Insider Ownership

Company	Insider Ownership
CBIO Crescent Biopharma	24.84%
EPRX Eupraxia Pharmaceuticals	N/A
PRME Prime Medicine	16.04%
SPRB Spruce Biosciences	4.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CBIO Crescent Biopharma	44	37.14 million	27.92 million	No Data
EPRX Eupraxia Pharmaceuticals	49	65.02 million	N/A	N/A
PRME Prime Medicine	146	181.38 million	152.28 million	N/A
SPRB Spruce Biosciences	8	2.87 million	2.75 million	Optionable

SPRB, PRME, CBIO, and EPRX Headlines

Recent News About These Companies

Spruce Biosciences (NASDAQ:SPRB) Stock Rating Reaffirmed as Market Outperform by Citizens Jmp

September 26 at 2:12 AM | americanbankingnews.com

Citizens Jmp Reaffirms "Market Outperform" Rating for Spruce Biosciences (NASDAQ:SPRB)

September 24, 2026 | marketbeat.com

Spruce Biosciences (SPRB) Reiterated at Market Outperform by Citizens on TA-ERT Therapy Lead

September 24, 2026 | streetinsider.com

Spruce Biosciences, Inc. (NASDAQ:SPRB) Given Consensus Rating of "Moderate Buy" by Analysts

September 23, 2026 | americanbankingnews.com

Spruce Biosciences (NASDAQ:SPRB) Coverage Initiated at Lake Street Capital

September 19, 2026 | americanbankingnews.com

Lake Street initiates coverage of Spruce Biosciences at buy

September 18, 2026 | msn.com

Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Average Recommendation of "Moderate Buy" from Brokerages

September 18, 2026 | marketbeat.com

Lake Street Capital Initiates Coverage on Spruce Biosciences (NASDAQ:SPRB)

September 17, 2026 | marketbeat.com

Spruce Biosciences to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026 | businesswire.com

Oppenheimer Sticks to Its Buy Rating for Spruce Biosciences (SPRB)

August 28, 2026 | theglobeandmail.com

Spruce Biosciences stock gains after analyst backs regulatory progress

August 27, 2026 | finance.yahoo.com

Spruce Biosciences Announces Launch of MPS3BStudy.com

August 26, 2026 | finance.yahoo.com

Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026

August 24, 2026 | finance.yahoo.com

Spruce Biosciences Inc.

August 16, 2026 | marketwatch.com

Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

August 12, 2026 | aol.comA

Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences

August 12, 2026 | finance.yahoo.com

Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development

August 3, 2026 | finance.yahoo.com

Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer

July 27, 2026 | finance.yahoo.com

Spruce Biosciences Names Adrian Quartel Chief Medical Officer

July 27, 2026 | tipranks.com

Spruce Biosciences to Participate in the B. Riley Securities 2026 Mind, Muscle & Vision Healthcare Summit

July 8, 2026 | finance.yahoo.com

Spruce Biosciences Possibly First In-MPS IIIB Class Enzyme Replacement Therapy

July 8, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB, PRME, CBIO, and EPRX Company Descriptions

Crescent Biopharma NASDAQ:CBIO

$14.76 +0.23 (+1.58%)

Closing price 04:00 PM Eastern

Extended Trading

$14.78 +0.02 (+0.14%)

As of 07:30 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Eupraxia Pharmaceuticals NASDAQ:EPRX

$8.31 +0.10 (+1.22%)

Closing price 04:00 PM Eastern

Extended Trading

$8.31 0.00 (0.00%)

As of 07:38 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Prime Medicine NASDAQ:PRME

$3.09 +0.21 (+7.29%)

Closing price 04:00 PM Eastern

Extended Trading

$3.09 0.00 (0.00%)

As of 07:58 PM Eastern

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof. We believe the ability to alter the human genome at the foundational level may confer the greatest therapeutic impact on human disease. Gene editing, including platforms such as Prime Editing, is a novel technology that is not yet clinically validated for human therapeutic use. Over the last decade, the field of genetic medicine has evolved tremendously, with groundbreaking advances in gene therapy, cell therapy, RNA therapy, and, more recently, gene editing. These technologies represent dramatic advancements for genetic therapies, but lack the versatility to precisely and efficiently correct the diverse range of mutations or DNA alterations implicated in disease. Prime Medicine was co-founded by a world-renowned leader in the field of gene editing, David Liu, Ph.D. Dr. Liu was joined as co-founder by Andrew Anzalone, M.D., Ph.D., who conceived of and developed Prime Editing technology. Drawn by the promise of Prime Editing’s ability to transform the field of gene editing, we have assembled a diverse team that has grown to more than 150 people as of September 30, 2022. There are no current plans for Dr. Liu to be an officer or director of our company following this offering. He is expected to continue to provide consulting services to us pursuant to a consulting agreement, which has a current term that runs through September 2025 and accommodates a previous commitment with respect to Beam Therapeutics Inc., which could result in or may create the appearance of a conflict of interest. He is also expected to retain his position and affiliation with the Broad Institute, Inc., Howard Hughes Medical Institute and Harvard University. On September 20, 2022, we achieved a major milestone as the United States Patent and Trademark Office, or the USPTO, issued U.S. Patent 11,447,770, or the ‘770 Patent, covering methods of using Prime Editors. The Broad Institute, Inc., or Broad Institute, prepared, filed and prosecuted the ‘770 Patent. While Broad Institute is the owner of the ‘770 Patent, it is exclusively licensed to us under the terms of the license agreement with Broad Institute. The ‘770 Patent is the first issued Prime Editing patent in our licensed patent portfolio and we believe it will be instrumental in protecting our Prime Editing platform and pipeline of gene editing programs. We believe our in-licensed and company-owned Prime Editing technology has transformative potential that could change the course of how disease is treated and overcome the challenges associated with current genetic therapies. We in-license our Prime Editing technology pursuant to a license agreement with Broad Institute. In addition, the license agreement grants us certain rights and licenses under certain patent rights Broad Institute owns or controls, including a license to the ‘770 Patent, which covers Prime Editing technology and expires in 2040. The licenses are limited to the field of prevention or treatment of human disease, and most licenses granted to us under the license agreement are further limited to the prevention or treatment of human disease by editing (including modifying or converting) or targeting DNA ex vivo, in vivo, or through xeno transplantation methods, which we refer to as the Prime Broad Field. We were incorporated under the laws of the State of Delaware in September 2019 under the name Prime Medicine, Inc. Our principal executive offices are located at 21 Erie Street, Cambridge, MA.

Spruce Biosciences NASDAQ:SPRB

$47.27 -0.24 (-0.51%)

Closing price 04:00 PM Eastern

Extended Trading

$48.16 +0.89 (+1.89%)

As of 07:59 PM Eastern

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SPRB, PRME, CBIO, and EPRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SPRB, PRME, CBIO, and EPRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SPRB, PRME, CBIO, and EPRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB, PRME, CBIO, and EPRX Company Descriptions

Crescent Biopharma NASDAQ:CBIO

Eupraxia Pharmaceuticals NASDAQ:EPRX

Prime Medicine NASDAQ:PRME

Spruce Biosciences NASDAQ:SPRB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SPRB, PRME, CBIO, and EPRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SPRB, PRME, CBIO, and EPRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SPRB, PRME, CBIO, and EPRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB, PRME, CBIO, and EPRX Company Descriptions

Crescent Biopharma NASDAQ:CBIO

Eupraxia Pharmaceuticals NASDAQ:EPRX

Prime Medicine NASDAQ:PRME

Spruce Biosciences NASDAQ:SPRB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools